Zobrazeno 1 - 2
of 2
pro vyhledávání: '"M. Hernández-Garfella"'
Autor:
J. L. Martín-Varillas, L. Sanchez-Bilbao, V. Calvo-Río, A. Adan, I. Hernanz Rodriguez, E. Beltrán, S. Castro, P. Fanlo Mateo, A. García Martos, I. Torre-Salaberri, M. Cordero-Coma, J. De Dios-Jiménez Aberásturi, Á. García-Aparicio, M. Hernández-Garfella, A. Sanchez-Andrade, A. García-Valle, R. Miguélez, O. Maiz, S. Rodríguez Montero, A. Urruticoechea-Arana, R. Veroz Gonzalez, A. Conesa, C. Fernández-Carballido, V. Jovani, O. Martínez González, P. Moya, S. Romero-Yuste, P. Rubio Muñoz, E. Peña Sainz-Pardo, M. Garijo Bufort, J. L. Hernández, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1013.2-1014
BackgroundAdalimumab remains the only biologic approved by the EMA and FDA for the treatment of non-infectious uveitis [1-6]. The reports on efficacy of other anti-TNF drugs such as Certolizumab Pegol (CZP) are scarce.Objectivesto determine the effic
Autor:
V. Llorenç, M. Sainz-de-la-Maza, Á. García-Aparicio, A. Blanco, C. Hernando-Hernández, J. Cincunegui-Gutiérrez, P. Fanlo, H. Heras, O. García-García, M. Hernández-Garfella, R. Veroz Gonzalez, L. Rodriguez-Melian, V. Jovani
Publikováno v:
Annals of the Rheumatic Diseases. 81:1003-1003
BackgroundA personalized disease-specific treatment for non-infectious uveitis (NIU) is challenging. Around 50% of adults with NIU who required classic DMARDs or adalimumab in clinical trials, failed at 6 months during open label phase [1,2]. Therefo